Literature DB >> 399045

[Reactivity of the intradermal test with toxoplasmosis in schizophrenic patients].

G Delgado García, J García Landa.   

Abstract

A hundred schizophrenic patients admitted to the "10 de Octubre" Clinical-Surgical Teaching Hospital and 158 schizophrenic patients admitted to the Psychiatric Hospital, both in Havana, and 100 control healthy individuals who did not consume psychopharmacons were studied. They underwent intradermal tests with toxoplasmin. Differences in reactor percentages between patients and healthy individuals were statistically significative as it has been reported in the foreign medical literature. The highest percentage of reactors in the group admitted to the Psychiatric Hospital where most advanced schizophreniacs are found leads to the conclusion that the more severe the patient state the higher the frequency and intensity of test reactivity among patients. Other factors as the dwelling conditions, age and sex are analyzed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 399045

Source DB:  PubMed          Journal:  Rev Cubana Med Trop        ISSN: 0375-0760


  3 in total

Review 1.  Toxoplasmosis and neuropsychiatric diseases: can serological studies establish a clear relationship?

Authors:  Silvia Fabiani; Barbara Pinto; Fabrizio Bruschi
Journal:  Neurol Sci       Date:  2012-09-26       Impact factor: 3.307

2.  Toxoplasma infection in schizophrenia patients: a comparative study with control group.

Authors:  A Alipour; S Shojaee; M Mohebali; M Tehranidoost; F Abdi Masoleh; H Keshavarz
Journal:  Iran J Parasitol       Date:  2011-06       Impact factor: 1.012

3.  Seroepidemiology of Toxoplasma gondii infection in psychiatric inpatients in a northern Mexican city.

Authors:  Cosme Alvarado-Esquivel; Olga-Patricia Alanis-Quiñones; Miguel-Angel Arreola-Valenzuela; Alfredo Rodríguez-Briones; Luis-Jorge Piedra-Nevarez; Ehecatl Duran-Morales; Sergio Estrada-Martínez; Sergio-Arturo Martínez-García; Oliver Liesenfeld
Journal:  BMC Infect Dis       Date:  2006-12-19       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.